UPDATE: Rodman & Renshaw Lowers PT to $4 on Geron
A report from Rodman & Renshaw reiterates its Market Outperform rating and lowers its price target from $9 to $4 on Geron (NASDAQ: GERN).
The report states, “…an analysis of other regenerative medicine companies at a similar stage of development and the inclusion of a 25% premium for shares of Geron given the company advanced the first human clinical trial of hESCs. With the spinal cord injury trial enrolling, a broad Phase 2 program for Imetelstat underway, and partnerships with GE Healthcare and AngioChem, we believe Geron represents an attractive opportunity for the risk-oriented, long-term investor."
GERN closed yesterday at $2.39.
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We're Loving
